The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).
 
Debu Tripathy
Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Novartis; OncoPep; Pfizer
Research Funding - Novartis (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Tristan Curteis
Research Funding - Novartis (Inst)
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Denise A. Yardley
Consulting or Advisory Role - Athenex (Inst); Biotheranostics (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); R-Pharm (Inst); Sanofi/Aventis (Inst)
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Biomarin (Inst); Biothera (Inst); Clovis Oncology (Inst); Dana Farber Cancer Hospital (Inst); Genentech/Roche (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); NSABP Foundation (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Polyphor (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Novartis
 
Fabio Franke
No Relationships to Disclose
 
Govind Babu Kanakasetty
No Relationships to Disclose
 
Paul Wheatley-Price
Honoraria - AstraZeneca; Bayer; Merck; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Merck; Novartis; Pfizer; Roche Canada
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Young-Hyuck Im
No Relationships to Disclose
 
Radost Pencheva
Research Funding - Novartis (Inst)
 
David Chandiwana
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Purnima Pathak
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Brad Lanoue
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)